Nippon Life Global Investors Americas Inc. Sells 3,740 Shares of IQVIA Holdings Inc. $IQV

Nippon Life Global Investors Americas Inc. trimmed its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 6.0% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 58,130 shares of the medical research company’s stock after selling 3,740 shares during the period. Nippon Life Global Investors Americas Inc.’s holdings in IQVIA were worth $11,041,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the stock. Versant Capital Management Inc grew its holdings in IQVIA by 6.3% in the third quarter. Versant Capital Management Inc now owns 899 shares of the medical research company’s stock worth $171,000 after purchasing an additional 53 shares during the period. Private Trust Co. NA grew its stake in shares of IQVIA by 12.5% in the 2nd quarter. Private Trust Co. NA now owns 603 shares of the medical research company’s stock valued at $95,000 after buying an additional 67 shares during the period. E Fund Management Co. Ltd. raised its stake in IQVIA by 3.7% during the 2nd quarter. E Fund Management Co. Ltd. now owns 2,099 shares of the medical research company’s stock worth $331,000 after buying an additional 74 shares during the period. Harbor Capital Advisors Inc. boosted its holdings in IQVIA by 2.9% in the third quarter. Harbor Capital Advisors Inc. now owns 2,795 shares of the medical research company’s stock worth $531,000 after acquiring an additional 78 shares in the last quarter. Finally, Hemington Wealth Management increased its holdings in shares of IQVIA by 43.4% during the third quarter. Hemington Wealth Management now owns 261 shares of the medical research company’s stock valued at $49,000 after acquiring an additional 79 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Cowen downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Monday, November 3rd. HSBC upgraded shares of IQVIA from a “hold” rating to a “buy” rating and lifted their price objective for the company from $195.00 to $235.00 in a report on Thursday, October 9th. BMO Capital Markets initiated coverage on shares of IQVIA in a research report on Thursday, November 13th. They issued an “outperform” rating and a $260.00 price target on the stock. Baird R W upgraded IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 29th. Finally, Mizuho set a $266.00 price objective on IQVIA in a research note on Friday, January 9th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $249.19.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the firm’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the sale, the insider directly owned 27,108 shares of the company’s stock, valued at $5,955,627.60. This trade represents a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 1.60% of the company’s stock.

IQVIA Trading Down 1.3%

NYSE IQV opened at $238.03 on Friday. The business’s fifty day moving average is $227.30 and its 200-day moving average is $203.34. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70. The stock has a market capitalization of $40.54 billion, a price-to-earnings ratio of 32.65, a PEG ratio of 2.42 and a beta of 1.36. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The business had revenue of $4.10 billion during the quarter, compared to the consensus estimate of $4.07 billion. During the same quarter last year, the company posted $2.84 earnings per share. The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Equities research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.